Pulmonary arterial hypertension (PAH), a chronic lung disease with poor prognosis, is characterized by progressively increasing blood pressure in the pulmonary vasculature. The normal resting mean pulmonary arterial pressure in healthy adults is ~14 mmHg at rest, whereas it is >25 mmHg in adults with PAH (1). PAH is usually secondary to conditions such as collagen vascular diseases, cardiac malformations and viral infections, and is currently believed to be associated with endothelial dysfunction, vasoconstriction and pulmonary vascular remodeling. Endothelial dysfunction, which is associated with an imbalance between vasodilators [e.g., nitric oxide (NO) and prostacyclin] and vasoconstrictors [e.g., endothelin (ET), thromboxane A2 and serotonin], is considered to be an early event during the process of PAH (2). A series of events leads to excessive proliferation of lung smooth muscle cells, activation of lung fibroblasts, induction of thrombotic mediators and release of inflammatory cytokines, all of which increase pulmonary vascular resistance and stress. One cause of vascular endothelial dysfunction and vascular injury is activation of the renin-angiotensin system (RAS). This results in overactivation of the angiotensin-converting enzyme (ACE)-angiotensin II (Ang II)-angiotensin II receptor type 1 (AT1R) axis, which involves ACE, vasoactive peptides and blood vessels. Ang II and its receptor, AT1R, exert adverse effects on pulmonary hemodynamics and may cause PAH (3). Myocardial infarction (MI) may lead to post-capillary PAH, increased left ventricular filling pressure, ventricular remodeling, even heart failure (4,5). Left ventricular failure leads to an increase in PAH and right ventricular afterload, which, in turn, leads to right ventricular remodeling and dysfunction. The PAH caused by left heart disease is mainly associated with left ventricular systolic or diastolic dysfunction or valvular heart disease, and has a poor prognosis (1,6). Persistent high pulmonary pressure may worsen endothelial dysfunction, reduce NO utilization and increase ET expression (4). Early-stage PAH associated with left heart disease may be reversible. However, the cardiac remodeling associated with long-term PAH may prevent reversal of PAH. PAH is the most common complication of congestive heart failure (7). Both hemodynamic factors and various molecular mechanisms contribute to the development of PAH after MI. In particular, in individuals with chronic PAH, a combination of mechanical pressure and histopathological reactions promotes progression of PAH, which ultimately becomes irreversible. The aim of the present review was to provide a comprehensive overview of the pathophysiological effects of multiple systems in MI and PAH, particularly regarding interactions between cardiomyocytes (CMs) and pulmonary vascular cells in post-MI PAH.

There is considerable evidence that the RAS contributes to the pathogenesis of PAH. High concentrations of renin, ACE, Ang II and AT1R have been documented in experimental models, as well as in patients with PAH (8-11). Increased activity of the RAS, systemically and in the pulmonary circulatory system, may adversely affect heart and lung function and contribute to disease progression. However, drugs that block the classical RAS, such as ACE inhibitors and AT1R blockers, reportedly have adverse effects when used to treat PAH, including drug-induced systemic hypotension, cough and angioedema (12). The advisability of blocking the RAS is controversial, as it plays a vasoprotective role in certain cardiovascular diseases.

As the pulmonary vasculature is more sensitive compared with the systemic vasculature to the contractile effects of AngII (8,9), AngII plays an important role in the pulmonary vascular circulation. Myocardial tissue can express RAS locally via a paracrine pathway (13). MI can trigger activation of the RAS, the long-term activation of which may cause myocardial damage; in this setting, AngII exerts a negative effect (14). When the circulating blood volume or renal blood flow is reduced, the paracellular cells of the juxtaglomerular apparatus secrete renin into the blood. This hydrolyzes the angiotensinogen produced by the liver into the decapeptide angiotensin I (AngI). In the pulmonary circulation, AngI is hydrolyzed to the octapeptide AngII by a converting enzyme present in the endothelial cells (ECs) of the pulmonary vasculature. AngII exerts different biological effects by binding to two subtype receptors, namely AT1R and AT2R. AT1R causes vasoconstriction, cell proliferation, inflammation and fibrosis through the ACE/AngII/AT1R signaling pathway, whereas AT2R protects the lungs through the ACE2/Ang-(1-7)/Mas receptor signaling pathway (15,16). In patients with PAH, as well as in experimental models, renin, AngII, ACE and AT1R are all increased to varying degrees in the blood. Additionally, the ratio of AT1R/AT2R and the expression of AT1R are increased (11,17). However, it remains unclear whether the increase in the levels of these hormones is a direct result of PAH, or whether it is mainly caused by the decrease in cardiac function caused by PAH.

Increased expression of AT1R and AT2R has been demonstrated in CMs in non-infarcted areas following MI. In vitro, acidosis promotes death of CMs and AngII enhances this effect (18). There is increasing evidence that AngII induces apoptosis of lung parenchymal cells, causing pulmonary vascular remodeling that ultimately leads to PAH, and that it also induces hypertrophy of CMs, inflammation and fibrosis during cardiac ischemic injury. This leads to ventricular remodeling and further impairment of cardiac function (12,19). It has been established that RAS is activated by a decline in cardiac function after MI, and that PAH is caused by both mechanical pressure and contraction mediated by AngII and vascular remodeling. The resultant further impairment of cardiac function in turn promotes the development of PAH (18,20). The initiation and development of chronic PAH originate from pulmonary vascular EC dysfunction. Endothelial damage increases the production of AngII in lung tissue (20), which both exacerbates contraction and remodeling of pulmonary vessels and adversely affects CMs. The evidence mentioned above indicates that AngII plays an important role in both MI and PAH. Of note, there are different degrees of AT1R/AT2R imbalance in MI and PAH. These findings indicate that there is a vicious circle between myocardial damage and pulmonary vascular response; they also provide a new perspective on the association between myocardial and pulmonary blood vessels. Further study of these mechanisms may indicate new approaches to the effective treatment of PAH (Fig. 1).

Reactive oxygen species (ROS) play a key role in regulating contraction/expansion, cell growth, apoptosis, migration, inflammation and fibrosis. Superoxide anions, hydrogen peroxide, hydroxyl radicals, reactive nitrogen, NO and peroxynitrite all serve important biological roles in the cardiovascular system. NADPH oxidase 2 (NOX2), which is a major source of ROS in the heart, is activated by MI, resulting in the generation of large amounts of ROS. NOX may be activated by several other noxious stimuli, including AngII, tumor necrosis factor (TNF)-α, vascular endothelial growth factor (VEGF) and shear stress (21). In addition, under hypoxic conditions, oxygenated myoglobin in CMs can produce an abundance of ROS (22). After an MI, ROS increase significantly in non-infarcted myocardium. Pulmonary blood vessels may be stimulated by the resultant changes in blood flow (23). Increased ROS production is involved in ventricular remodeling and heart failure after MI. A growing body of evidence supports the role of large amounts of ROS in the development and progression of PAH. Increased amounts of oxidative stress markers have been detected in the urine and plasma of patients with PAH. Additionally, histological examination of lung sections from such patients has revealed large amounts of by-products of oxidative stimuli (24,25). Experimental reduction of ROS levels combined with the use of antioxidants may enhance the response to the vasodilator NO in the pulmonary arteries. Inhibition of NOX or treatment with ROS scavengers may inhibit the development of chronic hypoxic PAH (26). ROS can reportedly promote pyruvate kinase M2 (PKM2) phosphorylation and inhibit the glycolytic activity of PKM2. This leads to proliferation of pulmonary artery smooth muscle cells (PASMCs) and maintenance of their antioxidant responses (27). Excessive ROS generation not only promotes AngII-mediated vascular remodeling, but also reduces vascular responses to NO. ROS have been demonstrated to play a key role in promoting the proliferation of pulmonary artery smooth muscle and EC damage associated with PAH (28). Pulmonary vascular ECs can also produce ROS. Additionally, ROS may act as signaling molecules that induce an increase in the amount of intracellular Ca²⁺, including in the cytoplasm of pulmonary ECs, which causes cell damage (26). Of note, AngII is also involved in the pathogenesis of ROS-mediated myocardial and pulmonary vascular cell damage and plays a key role in the cardiovascular system by activating NOX on cell membranes (29). AngII not only exacerbates CM injury to through direct action, but also promotes apoptosis of pulmonary parenchymal and vascular cells and pulmonary vascular remodeling, which stimulates almost all types of vascular cells to produce large amounts of ROS (30). There is some evidence that ROS produced post-MI can affect lung ECs and that AngII is also involved in ROS-mediated EC injury. However, the pathological mechanism of post-MI PAH has not been studied and warrants investigation. In PAH, large amounts of ROS are harmful to the already damaged heart, which further impairs cardiac function. Deterioration in cardiac function increases blood flow shear force in the pulmonary arteries, which impairs pulmonary vascular function (Fig. 2).

Endothelin (ET) has three isoforms, namely ET-1, -2 and -3. ET receptors are differentially expressed among different tissues and organs, and they are coupled with at least four known G proteins, the resultant complexes being ET_A, ET_B1, ET_B2 and ET_C. ET_B1, ET_B2 and ET_C have different binding affinities (31). The ET pathway in the pulmonary circulation is composed of ET-1, ET_A and ET_B (i.e., ET_B1 and ET_B2), with ET-1 exhibiting high-affinity binding (32). ET_A and ET_B receptors are present in smooth muscle cells and promote vasoconstriction and cell proliferation. ET_B receptors are also present in ECs; however, they promote vasodilation by releasing NO, prostacyclin and other endothelium-dependent vasodilators. Endogenous ET-1 mainly exerts its vasoconstrictive effect through ET_B on smooth muscle cells. However, the role of ET_A in the pulmonary vascular circulation has not yet been clearly determined (33-36).

Enhancement of ET system activity is associated with the severity of PAH. ET receptor antagonists have therefore been used clinically to treat PAH. They have been shown to have beneficial effects on PAH morbidity and mortality, emphasizing the important role of ET-1 in the development of PAH. The drug treatment of PAH is currently in its early stages, and there are currently no known drugs that can completely reverse PAH. However, two drugs appear to be somewhat effective, namely the dual (ET_A and ET_B) ET receptor antagonist bosentan and the selective ET receptor antagonist ambristan. However, their efficacy is restricted by their limited ability to penetrate tissue (37-39). Expression of ET-1 is mainly detected in the ECs of the pulmonary artery and may lead to intimal fibrosis and thickening of the media. Increased immunoreactivity of ET-1 in the pulmonary microcirculation and high plasma concentrations of ET-1 are directly associated with high right atrial pressure, low pulmonary oxygen saturation, and high pulmonary vascular resistance. Accumulating evidence suggests that ET-1 is pathophysiologically involved in the development of myocardial ischemia and infarction. It has been demonstrated that plasma ET-1 concentrations are significantly higher in patients with MI compared with those in healthy individuals (40).

Current research indicates that ET-1 plays an important role in vasoconstriction and pulmonary microcirculation remodeling. van Duin et al performed pulmonary vein banding on pigs and found that, over time, pulmonary artery pressure and resistance increased significantly. Pre-ET-1 and ET-converting enzyme-1 also increased in the lungs, as did ET mRNA expression, with resultant pulmonary vasoconstriction. However, sensitivity to ET decreased with increased pulmonary vascular contractility, which indicates that ET-1 plays an important role in pulmonary vascular remodeling in post-MI PAH (41). Similarly, in a study using a swine model of MI, Merkus et al observed stronger ET-mediated vasoconstriction in the pulmonary circulation, decreased bioavailability of NO, and impairment of the vasodilation mediated by prostaglandin compared with swine without MI. All these changes could be normalized by ET_A/ET_B receptor blockade (42). Satwiko et al used ET transgenic mice to study the correlation between PAH and ET and found that targeted activation of ET-1 exacerbated hypoxia-induced PAH. Their findings indicate that the pulmonary arteries are more susceptible to ET-1-mediated vasoconstriction compared with the systemic arteries, which further emphasizes the importance of ET-1 in the development of PAH (43). Others have also reported evidence that enhanced ET system activity may be a causative factor in the development of PAH (44,45), which provides a theoretical basis for treating PAH by inhibiting the ET system.

ET-1 is synthesized and released from blood vessels and endocardial ECs, as well as muscle cells. Of note, in patients with coronary artery spasm, MI and congestive heart failure, the amounts of ET-1 increase to varying degrees. In a porcine myocardial ischemia model, it was found that even transient blockage of coronary blood flow resulted in increased ET-1 production (10). It has also been reported that the mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK-ERK1/2) signaling pathway was a key regulator of ET-1 and ET_B receptors in the myocardium and coronary arteries after ischemia-reperfusion (I/R) in a rat model (40). Myocardial cells are subject to ischemia. Reperfusion stimulation enhances transcriptional expression of ET-1 and vasoconstrictive ET_B receptors via the MEK-ERK1/2 signal transduction pathway. The vasoconstrictor response to ET-1 in the heart is mainly mediated by ET_A receptors in vascular smooth muscle cells (VSMCs), whereas vasodilation is mediated by ET_B receptors located in the endothelium. It has been demonstrated that there is a phenotypic transformation of ET_B receptors in coronary VSMCs, the phenotype changing from diastolic to contractile (46); this means that, in the case of myocardial injury, ET-1 may cause coronary artery contraction and exacerbate myocardial ischemia through systolic ET_B receptors. It remains unclear whether the ET-1 pathway is directly involved in the development of PAH following myocardial ischemic injury. Additionally, additional incompletely characterized intercellular interactions may be responsible for the failure to develop effective treatments for PAH (Fig. 3).

VEGFs, a family comprising VEGF-A, -B, -C, -D and -E, and placental growth factor, are named in accordance with the number of constituent amino acids, e.g., VEGF121 and VEGF145. VEGF165 is the predominant VEGF-A isoform, the others being VEGF165, VEGF189 and VEGF206 (47). VEGF-A promotes vascular EC growth and migration and induces angiogenesis in a variety of in vivo animal models. VEGF-A165 is the most abundant and biologically active VEGF-A isoform. VEGF-A165 is primarily expressed in a variety of tumors, and its expression level is associated with tumor activity (e.g., development, invasion and metastasis) (48). The VEGF receptor (VEGFR) family consists of three subtypes: VEGFR-1, -2 and -3. All three receptor subtypes contain seven immunoglobulin-like domains in the extracellular region and a tyrosine kinase domain in the intracellular region. VEGFR-1 and VEGFR-2 are expressed in ECs and hematopoietic stem cells (47,49). VEGFR-1 is also expressed in monocytes and macrophages. By contrast, VEGFR-3 is only expressed in lymphatic ECs. The VEGF protein has a different affinity for each of the three VEGFR subtypes. VEGF-A is capable of activating VEGFR-1 and VEGFR-2; however, VEGFR-1 binds VEGF-A with an affinity 10-fold that for VEGFR-2. VEGF-VEGFR-2 signaling is crucial for vascular development and maintenance, whereas VEGFR-1 is an anti-angiogenic decoy receptor for VEGF and is required for normal vascular development (49,50).

After an MI, the expression of VEGF is upregulated in the myocardium and the peripheral blood, promoting angiogenesis and improving cardiac function (51). Therefore, several studies have used experimental animal models to investigate whether increasing the amount of VEGF in myocardial tissue protects CMs and improves cardiac function. One example is the use of collagen-binding domain specific for myocardial extracellular matrix in animals with chronic infarction. In one of these studies, modified VEGF was injected into the myocardium adjacent to the infarct in pig hearts, which resulted in angiogenesis and subsequent formation of CMs in the infarcted area for up to 3 months (52). Similarly, other researchers have used nanoparticle technology to increase the amounts of VEGF in myocardial tissue, achieving similar results (53). As regard the treatment of preclinical MI, there have been many reports of successful promotion of angiogenesis in the infarcted myocardium after treatment with VEGF gene or protein. However, the responses to VEGF were found to be dose-dependent in clinical trials. Moreover, administration of large doses of recombinant VEGF protein has been found to result in various adverse effects (54,55).

VEGF-A, a mitogen and survival factor characteristic of vascular ECs, is expressed in the epithelial cells of the terminal respiratory region in the fetal and postnatal lung (56) and it exerts a strong effect on pulmonary angiogenesis. Some clinical and basic studies have found that plasma VEGF concentrations and the expression of VEGF and VEGFR in lung tissue increase with hypoxia (55-58). In animal models, blocking VEGF-A receptors with the VEGF inhibitor Sugen 5416 induces PAH (59). Some studies have demonstrated that Sugen 5416 induces proliferation of blood secretory ECs and apoptosis of human microvascular pulmonary ECs by activating aromatic hydrocarbon receptors (AhRs) (60-62). Sugen 5416 has also been demonstrated to induce proliferation of human PASMCs by inducing nuclear translocation of AhR under hypoxic conditions (62). The findings mentioned above suggest that apoptosis of pulmonary microvascular ECs and translocation of AhR into the nuclei of human PASMCs lead to proliferation of pulmonary artery smooth muscle, which may be the pathological mechanism underlying the development of PAH.

VEGF165b is a specific subtype of VEGF-A with anti-angiogenic effects (63). VEGF165b reportedly contributes to the pathophysiology of PAH, particularly idiopathic PAH (64). VEGFR-2, a transmembrane tyrosine kinase receptor that is primarily expressed in the pulmonary endothelium, is the major receptor involved in VEGF-A angiogenesis (65,66). Inhibition of VEGFR-2 reduces the density of blood vessels, inhibits formation of alveoli, and reduces the weight of the lungs of newborn rats compared with those of the control group. These pathological changes eventually lead to PAH (67,68). In addition, recombinant human VEGF-A treatment and VEGFA gene therapy can restore pulmonary vascular growth and lung structure, and help protect lung function in rats (69,70). It has been reported that the expression of VEGFR-2 is weak in patients with pulmonary bronchial dysplasia (71). There is some evidence indicating an important role of the VEGF-VEGFR-2 signaling axis in maintaining endothelial homeostasis. Recent studies have found that the activity of VEGFR-1 and VEGFR-2 is relatively balanced in ECs. Kivelä et al found that VEGFR-1-knockout ECs strongly express neuregulin-1 and heparin-binding epidermal growth factor via VEGFR-2-Notch signaling. Binding to erbB receptors on CMs results in induction of hypertrophy of CMs and cardiac angiogenesis (72). Neuroregulatory proteins (members of the epidermal growth factor family) are produced by endothelial and myocardial cells containing the receptor (erbB) of the ligand. Of note, neuroregulatory proteins from cardiac ECs can slow hypoxia-related death of CM_S and reoxygenation through the paracrine effects of CMs (73). Taken together, these findings indicate that VEGF plays an important and unique role in the heart and lungs. On the one hand, VEGF affects angiogenesis and myocardial survival in infarcted myocardium (52,53); on the other hand, VEGF acts on various complex pathophysiological mechanisms in ECs, particularly the balance of VEGFR-1 and VEGFR-2 in ECs (72). This determines its signal transduction direction, thereby affecting the function of ECs. Both VEGF and its splice variants and several complex signaling pathways play important roles in PAH, similarly to bone morphogenetic protein receptor type II (BMPR2). The interaction between BMPR2 and VEGF also requires attention. It has been reported that absence of BMPR2 can inhibit VEGF signaling (74). Additionally, as mentioned earlier, VEGF is also implicated in pulmonary hypertension and myocardial injury by activating NOX to generate ROS, which indicates the existence of a complex regulatory network between organs. Differences in the pathophysiological effects of VEGF between CMs and pulmonary vascular ECs require further investigations in diseases such as post-MI PAH (Fig. 4).

The pathogenesis of PAH usually involves abnormalities in the bone morphogenetic protein (BMP) pathway. BMP is a secreted protein of the transforming growth factor (TGF)-β superfamily. A series of studies have documented that BMP signaling plays a key role in the cellular processes of proliferation, differentiation, and apoptosis in various tissues (75). In particular, it plays an important role in regulating cell pattern, differentiation, proliferation and apoptosis in the process of embryogenesis. BMP signaling is involved in promoting cell survival and proliferation in distal lung epithelial cells (76). Typical BMP signaling cascades can be divided into four subgroups as follows: BMP ligands, receptors, extracellular secretory antagonists and cell-reactive kinases. Over 20 BMP ligands have been identified to date. BMP-binding receptors are a group of transmembrane serine/threonine kinase receptors involved in type I (ALK2, ALK3 and ALK6) and type II (BMPR-II, ActR-IIa, and ActR-IIb) receptors (75). ALK1 is expressed on the surfaces of pulmonary vascular ECs, but not in PASMCs (77); ALK3 and ALK2 are expressed in both ECs and PASMCs (78); and BMPR-II is mainly expressed on the surface of pulmonary vascular ECs, but less strongly in smooth muscle and interstitial cells (79,80). BMP ligands initiate signal transduction by binding to type II receptors. They then recruit type I receptors and activate a range of intracellular kinases, including classic Smad signals and various mitogen-activated protein kinases. These signaling pathways are known to be involved in regulating cell proliferation, differentiation, mitosis, cell survival and apoptosis (75). BMP antagonists are secreted proteins that compete with specific BMP ligands for binding and, thus, inhibit their signal transduction. The main members of this protein family are noggin, follistatin, gremlin 1, matrix gla protein, chordin, twisted gastrin 1, and Bmper (81). BMP antagonists can inhibit BMP signaling by chelation of BMP ligands in a range of different cell types.

The BMP signaling pathway is involved in the pathophysiology of various diseases in adults. For example, an imbalance of BMP activity is associated with osteoarthritis and rheumatoid arthritis (82). Mutations in components of the BMP pathway are also associated with human gastrointestinal and cardiovascular diseases, such as PAH (83). There is evidence that ligands that are closely associated with BMP2 and BMP4 can cause upregulation of oxidative stress and inflammatory pathways in lung and coronary ECs. In addition, upregulation of BMP4 mRNA reportedly occurs in the lung after exposure to a hypoxic environment (84).

Evidence from patients with PAH and multiple well-defined experimental PAH models suggests that dysfunction of pulmonary artery ECs (PAECs) causes increased vascular permeability and excessive proliferation of PASMCs, inducing perivascular inflammation (85). Reduction in the barrier function of PAECs and pulmonary vascular remodeling are characteristic pathological characteristics of PAH. Abnormal morphological changes in BMP ligands are also closely associated with the pathogenesis of PAH. Hypoxia-responsive transcription factor hypoxia-inducible factor (HIF)-1α reportedly regulates BMP4 transcription by directly binding to the promoter region of the BMP4 gene and triggering BMP4 signaling (86). Han et al found that SMAD1 deficiency in endothelial or smooth muscle cells may render mice susceptible to PAH. This deficiency results in impairment of the balance between BMP4 and TGF-β1-mediated signaling pathways, indicating BMP downstream mediators. SMAD1 is also crucial for PAH-related BMPR-II signaling (87). In hypoxic PAH, high intracellular calcium concentrations play a key role in promoting contraction and proliferation of PASMCs. In PASMCs, hypoxia-triggered storage-operated calcium entry greatly promotes high intracellular calcium concentrations, which increase under hypoxic conditions. Hypoxia induces stabilization of HIF-1α (86). By transcriptionally activating BMP4 expression, BMP4 induces stronger expression of TORC1 and TRPC6. This triggers storage-operated calcium entry, which results in increased proliferation and migration of PASMCs (88). As regards BMPR-II-related EC function, Yang et al further demonstrated that adenovirus overexpression of BMPR-II mutant (kinase-deficient mutation, D485G) in PAECs not only promotes their apoptosis, but also induces secretion of growth factors (89). These findings suggest that abnormalities in BMP signaling lead to increased EC dysfunction and vascular permeability, and promote vascular smooth muscle cell proliferation, further contributing to the development and exacerbation of PAH. Recent research on the treatment of PAH has shown that inhibiting BMPs by increasing the expression of BMPR-II and inhibiting BMP ligand antagonists can ameliorate this condition.

Recent studies have demonstrated that expression of BMP-2 increases, whereas that of BMP-4 decreases when CMs are mechanically stimulated, as occurs when BMP2 and BMP2 autocrine/paracrine factors regulate the mechanical conduction and mechanical stretch of CMs (90). There is evidence that BMP-mediated transient suppression of signal transduction can promote differentiation of CMs, and that BMP2 increases the contractility of CMs. Therefore, previous studies have investigated the potential of BMP for treating heart disease. For example, administration of recombinant BMP2 has been shown to reduce infarct size after MI in mice, even for mature CMs (91). Another study demonstrated that BMP2 treatment can induce c-kit cardiac stem cells to differentiate into functional CMs; thus, BMP2 can promote repair of infarcted myocardium, thereby improving cardiac function (92). Activation of BMP4 signaling promotes apoptosis after MI induced by I/R injury. Additionally, in vivo treatment with noggin reduces infarct size and inhibits pre-apoptotic signals while inhibiting Smad1 phosphorylation and JNK activation (91). The BMP antagonist gremlin 2 (Grem2) is required for early cardiac development and CM differentiation. It has been found that the adult heart strongly but transiently induces formation of Grem2 in the inflammatory phase of myocardial tissue repair following experimental induction of MI. In wild-type mice, intraperitoneal injection of Grem2 protein can reduce post-MI inflammation. It has been found that BMP2 interacts with TNF-α to induce expression of proinflammatory proteins and promote leukocyte adhesion in ECs. However, Grem2 specifically inhibits BMP2 and has been shown to control the extent of inflammatory cell infiltration by inhibiting classical BMP signaling (93).

The findings mentioned above indicate that BMP signaling is important for the normal development of the heart and pulmonary vessels, which suggests that there is BMP signal crosstalk between the heart and the pulmonary vessels, for which, however, there is currently no direct evidence. For example, the endogenous BMP antagonist Grem2, which is induced by MI, can alleviate inflammatory responses caused by MI. However, whether it can affect the BMP signaling of pulmonary vascular cells deserves further investigation. The role of BMP signaling in the early stages of post-MI PAH also warrants further investigation. Additionally, BMP2 exerts a positive effect on both CMs and pulmonary vascular cells, whereas BMP4 has a negative impact. Thus, when developing BMP-related treatments, signaling pathway crosstalk between multiple organs must be taken into consideration to ensure safety. However, the relevance of such crosstalk has not yet been determined (Fig. 5).

Adiponectin, an insulin-sensitizing hormone secreted by adipocytes that reduces endoplasmic reticulum stress and ROS in ECs (94), plays an important role in the resistance of these cells to oxidative stress. It has been reported that plasma adiponectin concentrations are significantly lower in patients with cardiovascular disease compared with those in healthy individuals. Of note, cardiac cells can also secrete adiponectin (95,96). Upregulation of the expression of adiponectin in microvascular ECs and CMs of diabetic mice slows ischemic injury of the myocardium and improves cardiac function. Additionally, the adiponectin gene is regulated by HIF-1 (97). Experimental studies have demonstrated that HIF-1 protects the heart from acute I/R injury through transcriptional activation of cardiac protective genes (such as erythropoietin, heme oxygenase-1 and inducible NO synthase) (95). Interestingly, HIF-1α is currently considered to play a negative role in the BMP signaling pathway described earlier in this article. Thus, the research on the role of adiponectin in pulmonary vessels has been insufficient thus far. However, the abovementioned evidence provides new clues regarding the role of adiponectin in the heart and lungs and the pathological mechanism underlying post-MI PAH (Fig. 6).

There is currently sufficient evidence indicating that signaling pathways and action molecules are shared between the heart and lungs, and that these molecules are expressed to different degrees in the cardiac tissue and pulmonary vessels and play different roles in the circulation of the heart and lungs. The origins and development of diseases are not limited to the affected organ; rather, internal imbalance and dysregulation between organs usually underlies disease development. Research on the interaction between the heart and lungs is currently focused mainly on the effect of hypoxic PAH on the heart. The main therapeutic targets of PAH are ET-1, NO and prostacyclin; however, there are also RAS, VEGF, BMP, as well as other signaling pathways. The specific regulatory mechanisms of these signaling pathways remain unclear. Existing treatment protocols also have their limitations. Further studies are required to elucidate pathogenetic and pathophysiological factors, in order to enable diagnosis of these diseases by measuring the levels of identified pathology-related molecules, and reduction of their incidence by implementing effective preventive drug interventions at an early stage of the disease. This may both improve the effectiveness of treatment and greatly reduce the incidence of PAH caused by MI. The current challenge is to improve the understanding of the pathogenesis of post-MI PAH, including the mechanisms through which signal regulators affect PAH and the complexity of cardiopulmonary physiological characteristics. This would improve the efficacy of prevention and treatment of this condition. We believe that elucidating the mechanisms underlying cardiopulmonary interaction would not only improve our understanding of the pathological process of PAH post-MI, but may also provide a new basis and identify new therapeutic targets for the prevention and treatment of PAH.